Raising Our Fair Value Estimate for Shire

Shire's 3Q was in line with our expectations but we're boosting our fair value estimate on ADHD potential and Sanofi's extended Fabrazyme shortages

Karen Andersen, CFA 9 November, 2011 | 6:39PM
Facebook Twitter LinkedIn

Shire's (SHP) third-quarter performance was in line with our recently boosted assumptions for full-year 2011 performance. However, we're raising our fair value estimate due to recent developments in Shire's efforts to bring its ADHD franchise to Europe and continued shortages of a competing product in the Fabry disease market. Our five-year projected diluted earnings per share growth of 11% is still well below management's goals, and we continue to see shares as significantly overvalued.

Continue reading Morningstar analyst Karen Andersen's report on Shire here. Morningstar Equity Research is a feature of Morningstar.co.uk Premiuim subscription.

The information contained within is for educational and informational purposes ONLY. It is not intended nor should it be considered an invitation or inducement to buy or sell a security or securities noted within nor should it be viewed as a communication intended to persuade or incite you to buy or sell security or securities noted within. Any commentary provided is the opinion of the author and should not be considered a personalised recommendation. The information contained within should not be a person's sole basis for making an investment decision. Please contact your financial professional before making an investment decision.

Facebook Twitter LinkedIn

About Author

Karen Andersen, CFA  Karen Andersen, CFA, is a senior stock analyst with Morningstar.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures